Characterization and structural analysis of HIV-1 integrase conservation F Ceccherini-Silberstein, I Malet, R D’Arrigo, A Antinori, AG Marcelin, ... Aids Rev 11 (1), 17-29, 2009 | 177 | 2009 |
HIV-1 and HCV sequences from Libyan outbreak T de Oliveira, OG Pybus, A Rambaut, M Salemi, S Cassol, M Ciccozzi, ... Nature 444 (7121), 836-837, 2006 | 171 | 2006 |
An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus D Maione, CD Rocca, P Giannetti, R D'Arrigo, L Liberatoscioli, LL Franlin, ... Proceedings of the National Academy of Sciences 98 (11), 5986-5991, 2001 | 107 | 2001 |
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment S Aquaro, R D'Arrigo, V Svicher, GD Perri, SL Caputo, U Visco-Comandini, ... Journal of antimicrobial chemotherapy 58 (4), 714-722, 2006 | 94 | 2006 |
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure F Ceccherini-Silberstein, F Erba, F Gago, A Bertoli, F Forbici, ... Aids 18 (12), 11-19, 2004 | 88 | 2004 |
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels MM Santoro, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, ... Clinical infectious diseases 58 (8), 1156-1164, 2014 | 87 | 2014 |
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing D Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D’Arrigo, ... Journal of Infectious Diseases 205 (4), 557-567, 2012 | 73 | 2012 |
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations F Ceccherini-Silberstein, F Gago, M Santoro, C Gori, V Svicher, ... Journal of virology 79 (16), 10718-10729, 2005 | 67 | 2005 |
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors F Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, ... Journal of antimicrobial chemotherapy 65 (11), 2305-2318, 2010 | 63 | 2010 |
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group V Svicher, R D'Arrigo, C Alteri, M Andreoni, G Angarano, A Antinori, ... New Microbiologica 33 (3), 195-206, 2010 | 55 | 2010 |
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon J Fokam, R Salpini, MM Santoro, V Cento, R D’Arrigo, C Gori, CF Perno, ... Archives of virology 156, 1235-1243, 2011 | 47 | 2011 |
Subtype analysis and mutations to antiviral drugs in HIV‐1‐infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme MC Bellocchi, F Forbici, L Palombi, C Gori, E Coelho, V Svicher, ... Journal of medical virology 76 (4), 452-458, 2005 | 45 | 2005 |
Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3signatures in the regulation of Co-Receptor usage S Dimonte, F Mercurio, V Svicher, R D'Arrigo, CF Perno, ... Retrovirology 8, 1-11, 2011 | 44 | 2011 |
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz … V Tozzi, M Zaccarelli, P Narciso, MP Trotta, F Ceccherini-Silberstein, ... The Journal of infectious diseases 189 (9), 1688-1695, 2004 | 44 | 2004 |
Specific Enfuvirtide-Associated Mutational Pathways in HIV-1 Gp41 Are Significantly Correlated With an Increase in CD4+ Cell Count, Despite Virological Failure S Valentina, S Aquaro, R D'Arrigo, A Artese, S Dimonte, S Alcaro, ... The Journal of infectious diseases 197 (10), 1408-1418, 2008 | 43 | 2008 |
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs C Alteri, V Svicher, C Gori, R D'Arrigo, M Ciccozzi, ... BMC Infectious Diseases 9, 1-11, 2009 | 41 | 2009 |
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy M Zaccarelli, CF Perno, F Forbici, F Soldani, S Bonfigli, C Gori, MP Trotta, ... Clinical infectious diseases 38 (3), 433-437, 2004 | 38 | 2004 |
Molecular diversity of HIV in Albania M Ciccozzi, C Gori, S Boros, MJ Ruiz-Alvarez, A Harxhi, M Dervishi, ... The Journal of infectious diseases 192 (3), 475-479, 2005 | 36 | 2005 |
Macrophages: a crucial reservoir for human immunodeficiency virus in the body. E Balestra, CF Perno, S Aquaro, S Panti, A Bertoli, M Piacentini, F Forbici, ... Journal of biological regulators and homeostatic agents 15 (3), 272-276, 2001 | 36 | 2001 |
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs G Berno, M Zaccarelli, C Gori, M Tempestilli, A Antinori, CF Perno, ... BMC medical genetics 15, 1-7, 2014 | 32 | 2014 |